CRAI · CRA International, Inc. · Stock research

Reference close: $176.90 on 2026-08-21, from split/dividend-adjusted daily bars. All levels below are graded against that series.

CRAI — CRA International, Inc.

Current Thesis

Two weeks on from the 2026-08-06 beat-and-raise, the repricing is partial. Q2 FY2026 revenue printed $210.815M (+12.8% YoY, the highest quarterly revenue in company history) against $198.903M consensus, and FY2026 revenue guidance in constant currency went to $805–820M from $785–805M — the new floor is the old ceiling. The stock closed $169.31 on 2026-08-07 and $176.90 on 2026-08-21, which narrows the gap to the $221.74 52-week high from 23.6% to 20.2% and leaves a three-month price change of +19.8%. RSI(14) sits at 45.2.

The narrative leg is a toll on volume in two end-markets that ran hot in the June quarter: merger review and litigation. Management quantified the backdrop rather than gesturing at it — $1.6 trillion of global announced M&A in Q2 2026, case filings +11%, court judgments +5%, and a sixth consecutive record quarter for Antitrust & Competition Economics (2026-08-06 call). What has not arrived is margin. Roughly $12M of revenue upside produced a $0.01 non-GAAP EPS beat ($2.16 vs $2.15 consensus) and the non-GAAP EBITDA margin band was reaffirmed at 12.0–13.0% rather than lifted.

The narrative is maturing. Six consecutive record antitrust quarters is a known, working story, not a new one. Public news flow has been empty since the 2026-08-06 release — stockanalysis.com's CRAI news list carried no item dated after 2026-08-06 as of 2026-08-21 — and sell-side coverage is two analysts with a "Hold" consensus. Attention is not expanding; the operating story is still intact. That combination is the middle of the curve, not the front and not the back.

Bullish and bearish views on CRA International, Inc.

The model's bull view on CRA International, Inc. (CRAI), in brief: The beat was wide and the guide moved with it. The bear view: Operating leverage is absent so far. A ~$12M revenue beat converted to a penny of non-GAAP EPS. The 12.0–13.0% EBITDA margin band was reaffirmed, not raised — growth is being purchased with headcount and compensation. Receivables lengthened materially. Days sales outstanding… Both cases follow in full.

Bull Case

• The beat was wide and the guide moved with it. Revenue $210.815M vs $198.903M consensus on 2026-08-06; FY2026 constant-currency guidance to $805–820M from $785–805M, above the $801.21M pre-print consensus.
• The sell-side has marked to the raise. Three-analyst consensus for FY2026 revenue now sits at US$810.5M (Simply Wall St, post-2026-08-06) — mid-guide, meaning the raise is in the model and the low end is no longer the anchor.
• Both revenue inputs moved together. Utilization 77% with net headcount +3.3% in Q2 FY2026 (2026-08-06 call). Consulting revenue is headcount × utilization × rate.
• International +32.9% YoY, described on the 2026-08-06 call as organic growth in European Life Sciences and Antitrust, not acquired.
• A second demand line is forming, unquantified so far. Management flagged Energy-practice growth off utility data-center load forecasts and AI-driven complexity in Forensic Services and incident response (2026-08-06 call). No dollar figure has been disclosed for either.
• $0.57/share quarterly dividend declared 2026-08-06, record 2026-08-25, payable 2026-09-14.
• Financing capacity added. The credit facility was expanded on 2026-08-06 to a five-year $400M structure — $75M term loan plus $325M revolver — replacing a $300M revolver.
• The post-print level held. The 2026-08-07 close of $169.31 was not revisited on a closing look through 2026-08-21; the stock added 4.5% over those sessions on no fresh company headline.

Bear Case

• Operating leverage is absent so far. A ~$12M revenue beat converted to a penny of non-GAAP EPS. The 12.0–13.0% EBITDA margin band was reaffirmed, not raised — growth is being purchased with headcount and compensation.
• Receivables lengthened materially. Days sales outstanding moved to 113 days from 100 days in the prior quarter (2026-08-06 call). In labour-based consulting, that is the quality-of-earnings line to watch.
• 77% utilization is close to practical ceiling. Further revenue growth from here leans on hiring, and hiring is what capped the margin in Q2.
• The guide is stated in constant currency. With international revenue growing 32.9% YoY, reported revenue can diverge from the $805–820M path on FX translation without any change in demand.
• Coverage is thin and internally inconsistent. Two analysts, consensus rating "Hold", average price target $250.50 as of 2026-08-21 — roughly 41.6% above the reference close. A target that far from price alongside a neutral rating suggests the targets have not been marked to the de-rating.
• Nothing forces the gap closed before late October. No earnings, no guidance event and no scheduled company disclosure falls inside the next 30 days beyond a dividend record date.

Setup & Price Structure

Price: $176.90 (2026-08-21), against $169.31 (2026-08-07) and a $221.74 52-week high. The stock is 20.2% below that high eleven sessions after a record quarter, with a three-month price change of +19.8% and RSI(14) at 45.2. A 4.5% advance over two weeks that leaves RSI in the mid-40s is a recovery without momentum expansion — the buying has been enough to hold the post-print zone, not enough to trend it.

Two structural levels matter. The nearer one is $165: a weekly close under it puts price back beneath the 2026-08-07 post-print close and implies the raise has already been spent. The deeper one is $155, which surrenders the bulk of the three-month recovery leg and would date the 2026-08-06 print as a cycle high.

Crowding and positioning observables, stated as observed:

• Sell-side breadth is two to three analysts; consensus rating "Hold" (stockanalysis.com, 2026-08-21). There is no retail-sentiment clustering visible in coverage flow, and no message-board-driven volume event has been reported.
• No earnings date falls inside the next 30 days; the next print is estimated ~2026-10-29.
• Insider dispositions are small and plan-driven. A director's Form 4 reports 124 shares sold at $173.31 from a 2026-07-16 trade under a Rule 10b5-1 plan. Compensation mechanics rather than open-market sales. No large discretionary insider sale into the post-print recovery appears in the filings surfaced.
• The company itself was a net buyer in Q2 (~193,000 shares), with the buyback running while shares sat well below the 52-week high. The dollar amount of the buyback is not separately guided forward.

Catalyst Calendar (next 30 days)

• 2026-09-14 — Dividend payment date for the $0.57/share declared 2026-08-06.
• No scheduled earnings, guidance update or investor day falls inside the 30-day window. The next dated binary is the Q3 FY2026 print, estimated ~2026-10-29, which is where the $805–820M guide and the 12.0–13.0% margin band both get tested.

Elapsed catalysts

• 2026-08-25 — Dividend record date, $0.57/share. (passed 1d ago)

What Would Change Our Mind

The frame breaks on the fundamentals first. A Q3 FY2026 print (~2026-10-29, est.) that trims the $805–820M constant-currency guide, or that shows DSO extending beyond the 113 days reported for Q2, would recast the June quarter as the peak of the cycle rather than a waypoint. So would a second consecutive quarter where a large revenue beat lands an in-line EPS, which would settle the operating-leverage question in the negative and make the 12.0–13.0% EBITDA band a ceiling.

On price, the gradeable condition is a weekly close below $165: that surrenders the 2026-08-07 post-print close of $169.31 and prices the raise as fully spent, with $155 the level beneath it that ends the three-month recovery leg. A further break of the life-cycle label — coverage expanding to a mainstream retail bid while operating results flatten — would move this to saturated; the current two-analyst, no-news-flow configuration is the opposite of that.

The dividend record date on 2026-08-25 resolves nothing about demand. If it comes and goes with no change in the price structure, that is the expected outcome, and the read stays exactly where it is until late October.

Correlation Notes

• The revenue driver is announced M&A volume with a lag of a quarter or more, since expert-economics work follows a filing rather than an announcement. The $1.6 trillion global figure management cited for Q2 2026 is the observable to track for the Q4/Q1 revenue line, not the current one.
• Antitrust enforcement intensity is a policy variable, set by agency stance on merger review and Second Requests. It is not disclosed as backlog and does not move with equity beta, so a broad-market drawdown and a demand drawdown here are separate events.
• Closest listed comparables in expert services and litigation consulting are FTI Consulting (FCN) and Exponent (EXPO); Huron (HURN) and ICF International (ICFI) share the labour-utilization model with different end-markets. Read-across from those names is qualitative — no dated comparison of their prints to CRAI's is asserted here.
• The Life Sciences practice ties to pharma regulatory and commercialization spend. The 2026-07-07 BriaCell Therapeutics engagement of Charles River Associates for commercial strategy and market-access work is an example of that pipeline; no contract value was disclosed.
• With two covering analysts and a small index footprint, flows here are idiosyncratic. This name does not trade as a proxy for the AI-infrastructure or semiconductor complexes despite the AI-complexity commentary in Forensic Services.